[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thoracic-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thoracic-neoplasms":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,51,83,109,135,163,192,221,253,281,306],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100611589","phase-2-study-of-tarlatamab-as-maintenance-treatment-after-chemo-radiotherapy-for-limited-stage-sclc-patients-100611589",false,"NCT07242547","Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients","A Phase II Clinical Trial of Tarlatamab as Maintenance Treatment After Sequential Chemo-radiotherapy for Limited Stage SCLC Patients Not Eligible for Concurrent Chemo-radiotherapy","MERLIN","Inclusion Criteria:\n\n* Histologically or cytologically documented new diagnosis of LS-SCLC by histology or cytology from brushing, washing, or needle aspiration. Mixed tumors are not eligible.\n* Patients who:\n\n  1. were treated with sequential chemo-radiotherapy\n  2. were treated only with chemotherapy\n* Have at least one lesion that meets criteria for being measurable or non-measurable, as defined by RECIST 1.1.\n* Has completed chemo-radiation or chemotherapy alone without progression of disease per RECIST v1.1\n* Be male or female ≥18 years of age inclusive, on the day of signing informed consent.\n* Have a life expectancy of at least 3 months from the study start.\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days prior to the first dose of study intervention.\n* Toxicities attributed to chemo-radiotherapy treatment have to be resolved to grade ≤1, unless otherwise specified.\n* No clinically significant electrocardiogram (ECG) findings\n* Correct pulmonary function without oxygen supplementation\n* Have voluntarily agreed to participate by giving written consent for the study prior to any specific protocol procedures.\n* Have adequate organ function (hematological and biochemistry parameters).\n\nExclusion Criteria:\n\n* Patients expected to require any other form of radiation therapy for LS-SCLC as concurrent radiotherapy.\n* Extensive-stage SCLC (ES-SCLC) or any previous diagnosis of transformed non-small cell lung cancer. Mixed tumors (SCLC-NSCLC) are not eligible.\n* Has known history of, or active, neurologic paraneoplastic syndrome of autoimmune nature.\n* Has had major surgery within 4 weeks prior to first dose of study interventions.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.\n* Has known history of a second malignancy other than SCLC, unless potentially curative treatment has been completed with no evidence of malignancy for at least 3 years since the initiation of that therapy.\n* Uncontrolled intercurrent active infection at the time of enrollment requiring systemic therapy.\n* Evidence of interstitial lung disease or active, non-infectious pneumonitis.\n* History of solid organ transplantation.\n* Myocardial infarction and\u002For symptomatic congestive heart failure (New York Heart Association \\>class II) within 6 months prior to first dose of study treatment.\n* Has a known history of Human Immunodeficiency Virus (HIV) infection.\n* Has a known history of Hepatitis B or known active Hepatitis C virus infection.\n* Has a known history of active tuberculosis.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Has serious nonhealing wound, ulcer, or bone fracture within 28 days before first dose of study intervention.\n* Female subjects of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 60 days after the last dose of study treatment.\n* Female subjects who are breastfeeding or who plan to breastfeed while on study through 60 days after the last dose of study treatment.\n* Female subjects planning to become pregnant or donate eggs while on study through 60 days after the last dose of study treatment.\n* Female subjects of childbearing potential with a positive pregnancy test assessed at screening by a highly sensitive serum pregnancy test.\n* Male subjects with a female partner of childbearing potential who are unwilling to practice sexual abstinence or use contraception during treatment and for an additional 60 days after the last dose of study treatment.\n* Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 60 days after the last dose of study treatment.\n* Subject has known sensitivity to any of the products or components to be administered during dosing.","ALL","18 Years",{"count":20,"type":21},37,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is an open-label, phase II, exploratory and multi-centre clinical trial. 37 Limited stage SCLC patients not eligible for concurrent chemo-radiotherapy will be enroll.\n\nPatients will be enrolled in the trial after receiving sequential chemo-radiotherapy, if there is no progression disease, patients will be treated with maintenance Tarlatamab.\n\nPatients will receive maintenance with Tarlatamab IV until disease progression unacceptable toxicity, patient or physician decision to discontinue or death.\n\nThe primary objective is to evaluate the Progression free survival (PFS).\n\nPatient accrual is expected to be completed within 2 years. Treatment and follow-up are expected to extend the study duration to a total of 5 years. Patients will be followed for 2 years after enrollment. The study will end once survival follow-up has concluded.",[27,28,29,30],"Limited-stage Small-cell Lung Cancer","Carcinoma, Small Cell Lung","Respiratory Tract Neoplasms","Thoracic Neoplasms",[32,33,34,35,36,37],"Non small cell lung cancer","Tarlatamab","Maintenance treatment","Antineoplastic Agents","Chemo-radiotherapy","Immunotherapy","RECRUITING","2026-04-29",{"date":41,"type":42},"2026-05-05","ACTUAL",{"date":44,"type":21},"2026-05-28",{"date":46,"type":21},"2030-06-01",{"name":48,"class":49},"Fundación GECP","OTHER",20,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100629786","local-radiofrequency-ablation-plus-external-beam-radiation-for-the-treatment-of-painful-thoracic-and-lumbar-spine-tumors-100629786","NCT07479199","Local Radiofrequency Ablation Plus External Beam Radiation for the Treatment of Painful Thoracic and Lumbar Spine Tumors","Local Radiofrequency Ablation Plus External Beam Radiation for the Treatment of Painful Thoracic and Lumbar Spine Tumors -SPARC","Inclusion Criteria:\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Subjects is willing and able to comply with study procedures based on the judgement of the investigator.\n* Age ≥ 18 years at the time of consent.\n* Life expectancy beyond completion of protocol intervention of at least 1 month and deemed appropriate for treatment based on multidisciplinary review and\u002For investigator discretion.\n* Metastatic thoracic or lumbar spine tumor. Tumor should be lytic or mixed lytic\u002Fblastic. Note: there does not need to be a fracture.\n* Patient reported back pain of ≥ 5 on a VAS scale\n\nExclusion Criteria:\n\n* Active infection requiring systemic therapy.\n* Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).\n* Is currently taking Avastin or anti-coagulant meds that cannot be held.\n* Is currently enrolled in a cancer related clinical trial.",{"count":59,"type":21},70,"OBSERVATIONAL","This study looks at how well a combination of treatments helps reduce pain in people with tumors in the middle and lower back (thoracic and lumbar spine). All participants receive the same treatment, which includes a procedure to stabilize the spine (kyphoplasty), radiofrequency ablation will be with the Osteocool system and radiation therapy. The goal is to see how effective this combined approach is at relieving pain.\n\nThe purpose of this study is to find out whether combining these three treatments provides better pain relief for patients with thoracic and lumbar spine tumors. This study is for adults who have cancer that has spread to the thoracic or lumbar spine and who report moderate to severe back pain (a pain score of 5 or higher on a 0-10 pain scale).",[30,63],"Lumbar Neoplasm",[65,66,67,68,69,70,71,72],"pain","Radiofrequency Ablation","Local Radiofrequency Ablation","Radiofrequency","Ablation","External Beam Radiation","kyphoplasty","Osteocool","2026-04-21",{"date":75,"type":42},"2026-04-23",{"date":77,"type":42},"2026-03-16",{"date":79,"type":21},"2031-03-01",{"name":81,"class":49},"UNC Lineberger Comprehensive Cancer Center",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":82},"100605218","post-operative-medium-chain-triglyceride-diet-may-reduce-hospital-stay-following-lung-resection-100605218","NCT07159659","Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection","Inclusion Criteria:\n\nGeneral Inclusion Criteria for All procedures:\n\n1. Age between 18 - 80 years\n2. Body mass index \\\u003C35 kg\u002Fm2\n3. Suitable for minimally invasive surgery\n4. Willingness to participate as demonstrated by giving informed consent\n\nProject-specific Criteria:\n\n1\\. Patients performed lobectomy with lymph node dissection\n\nExclusion Criteria:\n\nPatient general exclusion criteria:\n\n1. Contraindication to general anesthesia\n2. Severe concomitant illness that drastically shortens life expectancy or increases the risk of therapeutic intervention\n3. Untreated active infection\n4. Non-correctable coagulopathy\n5. Emergency surgery\n6. Vulnerable population (e.g. mentally disabled, pregnancy)\n\nProject-specific Criteria\n\n1. Segmentectomy\n2. Pleurodesis\n3. Esophageal procedures\n4. Redo\u002Freadmitted patients for lung resection\n5. Chylothorax (Triglyceride \\> 110 mL, excluded at day 1 routine lab check)\n6. Air leak (\\> 30 mL\u002Fmin when back to ward)\n7. Heart Failure\n8. Renal failure (estimated GFR \\\u003C 30; CKD grading stage 4-5)\n9. Moderate to severe adhesion (defined at randomization by surgeon; criteria include estimated surface area of adhesion and staging)\n10. History of tuberculosis or empyema","80 Years",{"count":91,"type":21},210,[93],"NA","Lung resection, a critical treatment for various thoracic diseases, including lung cancer, often necessitates prolonged hospitalization due to rare but severe postoperative complications such as chyle leaks, with an occurrence of 0.25%-3%, prolonging chest drainage, and delaying recovery. Therefore, effective postoperative care is essential for optimizing outcomes, reducing complications, and expediting recovery.\n\nRecent studies have highlighted the significant potential of medium-chain triglyceride (MCT) diets, owing to their unique absorption pathway and metabolic properties. MCT contains mainly medium-chain fatty acids (MCFA), which is absorbed in the intestine and transported to the liver via the portal system instead of the lymphatic system. This helps to bypass the lymphatic system, thereby reducing the volume of lymph. MCFAs also provide better energy utilization in stressed condition since it does not require carnitine shuttle upon metabolism, which is beneficial to post-operation recovery.\n\nSeveral studies have demonstrated the benefits of MCT diets in managing chyle leaks and supporting gastrointestinal recovery, particularly in conditions that strain the lymphatic system. For instance, short-term MCT-enriched diets have been associated with improved post-operation recovery of gastrointestinal, hepatic and renal functions, reduced total chest drainage volumes, and shorter hospital stay when compared to regular diet groups.\n\nPatients with post-operative chyle leak following thoracic surgery are often given an MCT diet to reduce chest drain volume and hence shorten hospital stay. Based on the successful use of MCT diet on patients with chyle leak after lobectomy, it is hypothesized that patients with chylothorax provided with post-operative MCT diet can also shorten hospital stay by decreasing chest drainage. Therefore, a prospective and randomized trial is designed to investigate how post-operative MCT diet in lung resection patients without chylothorax may affect hospital stay and post-operative recovery.",[30],[97,98,99],"Medium Chain Triglyceride Diet","Lung Resection","Video-assisted thoracoscopic surgery","2026-03-18",{"date":102,"type":42},"2026-03-20",{"date":104,"type":21},"2026-03-19",{"date":106,"type":21},"2027-08-30",{"name":108,"class":49},"Chinese University of Hong Kong",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":82},"100479346","phase-4-erector-spinae-block-for-thoracic-surgery-100479346","NCT05521789","Erector Spinae Block for Thoracic Surgery","Erector Spinae Blocks for Thoracic Surgery","Inclusion Criteria:\n\n* pulmonary resection\n* 18\\\u003Cage\\\u003C90\n\nExclusion Criteria:\n\n* pleurodesis\n* decortication\n* emergent surgery\n* local anesthetic allergy\n* intraoperative complication (inadvertent hemorrhage or conversion to open surgery)\n* bilateral pulmonary resection","90 Years",{"count":59,"type":21},[119],"PHASE4","The aim of this study is to determine if erector spinae injections with bolus infusions with local anesthetic decrease postsurgical pain and opioid consumption in patients undergoing pulmonary resection surgery.",[122,123,124,125,30],"Pulmonary Neoplasm","Pulmonary Cancer","Thoracic Diseases","Thoracic Cancer","2026-02-23",{"date":128,"type":42},"2026-02-25",{"date":130,"type":42},"2022-07-22",{"date":132,"type":21},"2027-07-21",{"name":134,"class":49},"George Washington University",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":82},"100608744","phase-2-clinical-study-of-thiopegfilgrastim-for-preventing-bone-marrow-suppression-in-thoracic-tumor-chemoradiotherapy-100608744","NCT07205536","Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy","A Clinical Study on the Safety and Efficacy of Mecapegfilgrastim in Preventing Myelosuppression Induced by Concurrent Chemoradiotherapy for Thoracic Malignancies","ANC-IIT-004","Inclusion Criteria:\n\n* Aged 18-75 years at the time of giving informed consent， both sexes eligible\n* Histologically or cytologically confirmed thoracic tumor (esophageal or lung cancer)\n* Investigator judges the patient suitable for treatment with mecapegfilgrastim injection or leucogen tablets\n* Expected survival \\> 3 months\n* Signed informed consent; willing and able to comply with protocol-mandated visits\n* The patient is indicated for concurrent chemoradiotherapy and is currently\u002Freceiving or will receive a high-risk chemotherapy regimen for febrile neutropenia (FN risk ≥20%), or is currently\u002Freceiving or will receive an intermediate-risk chemotherapy regimen for FN (FN risk 10%\\~20%) with additional FN risk factors.\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Known hypersensitivity to mecapegfilgrastim, pegylated or non-pegylated rhG-CSF, or any E. coli-derived product\n* Any severe comorbidity that, in the investigator's opinion, compromises patient safety or ability to complete the study\n* Any other condition that, in the investigator's judgment, could interfere with study conduct or interpretation of results","75 Years",{"count":145,"type":21},30,[24],"This is a prospective observational study designed to observe and evaluate the safety and efficacy of mecapegfilgrastim in the treatment of moderate-to-severe myelosuppression associated with concurrent chemoradiotherapy. The project will provide more robust evidence-based medical support for the use of long-acting granulocyte-stimulating agents in patients undergoing concurrent chemoradiotherapy.",[149,30,150],"Myelosuppression","Chemoradiotherapy",[152,153],"Neutropenia","Febrile neutropenia","2025-12-10",{"date":156,"type":42},"2025-12-11",{"date":158,"type":42},"2025-08-01",{"date":160,"type":21},"2027-12",{"name":162,"class":49},"Affiliated Hospital of Nantong University",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":143,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":178,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":82},"100574393","phase-2-post-line-treatment-with-teniposide-for-c-myc-driven-extensive-stage-small-cell-lung-cancer-100574393","NCT06758700","Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer","Phase II Clinical Study to Evaluate the Efficacy and Safety of Teniposide as a Post-Line Therapy for c-Myc-Driven Extensive-Stage Small Cell Lung Cancer","Inclusion Criteria:\n\n1. extensive stage small cell lung cancer\n2. Progression after receiving at least one chemotherapy drug treatment in the past;\n3. ECOG score 0-1\n4. c-Myc-driven\n5. Expected survival period ≥3 months\n6. Age: 18-75 years old;\n7. The informed consent form complies with the ICH-GCP principles.\n\nExclusion Criteria:\n\n1. No measurable lesions\n2. Other severe and persistent diseases or organ system dysfunction;\n3. Women planning pregnancy or men planning family planning;\n4. Women who are pregnant or breastfeeding;\n5. Those who cannot follow the research protocol provided by the investigator.",{"count":171,"type":21},15,[24],"The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2\u002FMYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2\u002FMYC and the efficacy of teniposide.",[175,30,176,177],"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","Lung Neoplasms","Lung Diseases",[179,180,181,182],"c-Myc","SCLC","Phase II","Post-line","2025-11-30",{"date":185,"type":42},"2025-12-05",{"date":187,"type":42},"2025-02-07",{"date":189,"type":21},"2026-12-31",{"name":191,"class":49},"Shanghai Pulmonary Hospital, Shanghai, China",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":208,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":50},"100586607","phase-2-palace-cemiplimab-trial-according-to-ctdna-levels-100586607","NCT06917573","PALACE: Cemiplimab Trial According to ctDNA Levels","Phase II Clinical Trial With an Adaptive Design According to Response to Cemiplimab Monotherapy Using ctDNA and Subsequent Treatment With Chemotherapy (CT) and Cemiplimab or Cemiplimab Monotherapy in First Line Advanced NSCLC Patients","PALACE","Inclusion Criteria:\n\n* Histologically confirmed stage IV or stage IIIB\u002FC not candidates for definitive chemo\u002Fradiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therapy\n* PDL1 ≥50%\n* ECOG performance status 0-1\n* Patients aged ≥ 18 years\n* Prior adjuvant or neoadjuvant chemotherapy for early stage is permitted if completed at least 6 months prior to enrolment\n* Presence of at least one measurable lesion by CT-scan per RECIST version 1.1\n* Anticipated life expectancy \\>12 weeks\n* Correct hematological, hepatic and renal function\n* Patient consent must be obtained in the appropriate manner as established in the applicable local and regulatory requirements\n* Patients must be accessible for treatment and follow-up\n* Women of childbearing potential, including women who had their last menstrual period in the last 2 years, must have a negative serum or urine pregnancy test within 3 days before enrolment.\n* All sexually active men and women of childbearing potential must use a highly effective contraceptive method during the study treatment and for a period of at least 4 months following the last administration of trial drugs\n\nExclusion Criteria:\n\n* Patients whose tumors harbor an activating mutation in EGFR, ALK translocation, or ROS Proto-Oncogene 1 (ROS1) rearrangements sensitive to available targeted inhibitor therapy\n* Patients with grade ≥2 neuropathy\n* Pregnant or breastfeeding women\n* Patients with a weight loss \\>10% within the previous 3 months\n* Patients with carcinomatous meningitis\n* Patients with a history of other malignant diseases within the past 3 years\n* Patients must have recovered from a major surgery at least 14 days prior to enrolment\n* Patients with active or uncontrolled infections or with serious medical conditions or disorders that may not allow patient management as established in the protocol\n* Prior treatment with antineoplasic drugs or thoracic radiotherapy for any reason different from the ones specific in the inclusion criteria\n* Patients who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemo-radiotherapy with curative intent for non-metastatic disease less than 6 months before enrollment since the last chemotherapy, radiotherapy, or chemo-radiotherapy\n* Patients with a combination of small cell lung cancer and non-small cell lung cancer, a carcinoid lung tumor or large cell neuroendocrine carcinoma\n* Has known allergy or hypersensitivity to components of study drug\n* Significant comorbidities that preclude the administration of chemotherapy according to the investigator's criteria\n* Ongoing or recent evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments\n* Untreated brain metastasis(es) that may be considered active\n* Immunosuppressive corticosteroid doses within 4 weeks prior to the first dose of cemiplimab\n* Uncontrolled infection with hepatitis B or hepatitis C or human immunodeficiency virus; or diagnosis of immunodeficiency\n* History of interstitial lung disease or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management.\n* History of documented allergic reactions or acute hypersensitivity reactions attributed to antibody treatments\n* Patients with a history of solid organ transplant\n* Receipt of live vaccines within 30 days of first study treatment\n* Women of childbearing potential, or sexually active men, who are unwilling to practice highly effective contraception prior to the initial dose\u002Fstart of the first treatment prior to the start of the first treatment, during the study, and for at least 4 months after the last dose.",{"count":201,"type":21},63,[24],"This is an open-label, non-randomised, phase II, multicenter clinical trial. 63 stage IV or stage IIIB\u002FC not candidates for definitive chemo\u002Fradiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therapy will be enrolled in this trial to determine whether therapy decision making based on ctDNA analysis improves overall survival.",[205,177,206,207,29,30],"Non Small Cell Lung Cancer Metastatic","Stage IV Non-small Cell Lung Cancer","Stage III Non-small Cell Lung Cancer",[209,210,211,212],"Cemiplimab","ctDNA levels","Chemotherapy","Non-resectable non-small cell lung cancer","2025-11-17",{"date":215,"type":42},"2025-11-19",{"date":217,"type":42},"2025-07-29",{"date":219,"type":21},"2031-12-30",{"name":48,"class":49},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":228,"sex":17,"minAge":229,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":234,"conditions":235,"keywords":239,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":82},"100592093","early-intervention-strategies-for-lung-cancer-100592093","NCT06988943","Early Intervention Strategies for Lung Cancer","Construction and Evaluation of a Hospital-Community Health Collaboration Model Empowered by Digital Technology for Lung Cancer Screening","1.Community Health Service Centers (Cluster Level)\n\n1. Inclusion Criteria The community health service center must be located within one of the 11 districts of Guangzhou.\n\n   The center must manage a population of over 10,000 elderly individuals. The center should be equipped with at least one CT machine and have qualified medical personnel, such as radiologists, radiologic technicians, and nursing staff.\n2. Exclusion Criteria Community health centers currently participating in other public health projects or studies that may affect screening results.\n\nCommunity health service centers where researchers cannot collect data or conduct follow-up.\n\n2\\. Screening Subjects (Individual Level)\n\n1. Inclusion Criteria Aged 40-75 years. Residing in the community participating in the study for a long time. No known history of lung cancer and has not undergone lung cancer screening in the past three months.\n\n   Able to understand and willing to sign the informed consent form, and able to participate in long-term follow-up.\n2. Exclusion Criteria Individuals diagnosed with lung cancer. Individuals with severe other health issues that make them unsuitable for CT imaging.\n\nIndividuals unable to understand the study protocol or who cannot provide informed consent due to cognitive impairments.\n\nIndividuals participating in other clinical trials that may affect the results of this study.\n\nIndividuals unable to undergo follow-up.",true,"40 Years","74 Years",{"count":232,"type":21},16000,[93],"Low-dose CT (LDCT）can detect and treat lung cancer earlier and more quickly, while expanded screening coverage helps reduce the incidence and mortality of respiratory diseases such as lung cancer. This study aims to conduct a single-arm cluster randomized trial of digitally enabled LDCT in Guangzhou to assess its intervention effectiveness and cost-effectiveness.",[29,30,236,237,177,238,176],"Neoplasms by Site","Neoplasms","Respiratory Tract Diseases",[240,241,242,243],"Screning test","Lung cancer","LDCT","Low-dose CT","2025-05-26",{"date":246,"type":42},"2025-05-30",{"date":248,"type":42},"2024-06-25",{"date":250,"type":21},"2025-06",{"name":252,"class":49},"The First Affiliated Hospital of Guangzhou Medical University",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":228,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":263,"conditions":264,"keywords":265,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":82},"100524135","the-effects-of-a-family-centered-tai-chi-exercise-on-lung-function-and-mental-health-of-patients-after-thoracoscopic-surgery-100524135","NCT06104774","The Effects of a Family-Centered Tai Chi Exercise on Lung Function and Mental Health of Patients After Thoracoscopic Surgery","Vice Superintendent","Inclusion Criteria:\n\n1. Hospitalized to receive thoracoscopic lobectomy, wedge\u002Fpartial resection, lobectomy, or sleeve resection.\n2. American Society of Anesthesiologists (ASA) physiological status classification I-II (ASA, 2019).ASA Physical Status Class I: A healthy person who is healthy and does not smoke or drink.ASA physical status class II: People with mild chronic diseases but no substantial functional limitations.\n3. Those who can walk on their own without any impairment in limb movement.\n4. Able to communicate in Chinese or Taiwanese.\n\nExclusion Criteria:\n\n1. Individuals requiring chemotherapy and radiation therapy for malignant tumors.\n2. Those who have practiced Tai Chi, Qigong, external elixir exercises, or pulmonary exercises within the past year.\n3. Anticipating hospitalization or surgical treatment within the next three months.\n4. Individuals with musculoskeletal or peripheral vascular diseases.\n5. Individuals with visual impairment, intellectual disabilities, or memory loss.",{"count":261,"type":21},200,[93],"To explore the effect of a family-centered, eight-week, progressive sit-to-stand Tai Chi exercise on lung function and mental health in patients after thoracoscopic surgery\\_",[30],[266,241,267,268,269,270,271],"Tai Chi exercise","thoracoscopic surgery","Lung function","Mental Health","Sleep","Family-Centered","2025-04-20",{"date":274,"type":42},"2025-04-24",{"date":276,"type":42},"2023-10-20",{"date":278,"type":21},"2025-12-31",{"name":280,"class":49},"China Medical University Hospital",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":287,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":296,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":82},"100585040","optimizing-radiation-dose-and-utilizing-wearable-devices-to-reduce-arrhythmia-risk-in-patients-undergoing-thoracic-radiotherapy-a-prospective-cohort-study-100585040","NCT06897189","Optimizing Radiation Dose and Utilizing Wearable Devices to Reduce Arrhythmia Risk in Patients Undergoing Thoracic Radiotherapy: A Prospective Cohort Study","Inclusion Criteria:\n\n* Patients with solid tumors requiring thoracic radiotherapy\n* Undergoing curative-intent radiotherapy\n* Expected survival \\> 4 months\n* Adults aged ≥ 20 years\n* ECOG performance status 0-2\n* Classified as moderate-to-high risk for radiation-induced cardiotoxicity per the 2022 ESC guidelines\n* Able to read, understand, and sign the informed consent form\n\nExclusion Criteria:\n\n* History of prior thoracic radiotherapy\n* Inability to provide informed consent or refusal to participate\n* Pre-existing arrhythmia diagnosed through medical history or pre-treatment evaluation\n* Expected survival ≤ 4 months\n* Classified as low risk for radiation-induced cardiotoxicity per the 2022 ESC guidelines\n* Unsuitability for Wearable CR device use","20 Years",{"count":289,"type":21},111,"This prospective observational cohort study aims to assess the risk of radiation-induced cardiotoxicity in patients undergoing thoracic radiotherapy by integrating real-time arrhythmia monitoring using wearable cardiac rehabilitation (wearable CR) devices and AI-based cardiac substructure segmentation. The study will analyze radiation dose exposure to key cardiac structures, including the sinoatrial node (SAN) and pulmonary veins (PV), to identify risk factors for atrial fibrillation (AF) and other arrhythmias. Patients will receive wearable CR monitoring at 3, 12, and 24 months post-radiotherapy, with cardiology follow-up and intervention based on standard clinical guidelines. The study will recruit 111 patients over three years, with a two-year follow-up after radiotherapy. The primary endpoint is the incidence of grade 3+ AF within 2 years, with secondary outcomes including any-grade arrhythmia rates, arrhythmia burden, and survival analysis. By establishing a prospective thoracic radiotherapy patient cohort, this study aims to identify dose-related risk factors, improve early detection and management of radiation-induced arrhythmias, and provide evidence-based strategies to enhance treatment safety and efficacy.",[292,293,294,30,295],"Cardiotoxicity","Thoracic Radiotherapy","Wearable Electronic Devices","Atrial Fibrillation","NOT_YET_RECRUITING","2025-04-16",{"date":299,"type":42},"2025-04-18",{"date":301,"type":21},"2025-05",{"date":303,"type":21},"2030-02-16",{"name":305,"class":49},"Yonsei University",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":143,"enrollmentInfo":313,"targetDuration":4,"studyType":22,"phases":315,"briefSummary":316,"conditions":317,"keywords":321,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":82},"100529757","phase-2-a-phase--clinical-study-of-adebrelimab-combined-with-chemotherapy-and-concurrent-radiotherapy-for-extensive-stage-oligometastatic-sclc-100529757","NCT06177925","A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC","A Phase Ⅱ Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Extensive-Stage Oligometastatic Small Cell Lung Cancer","Inclusion Criteria:\n\n* Signed inform consent form\n* Age \\>= 18 years and \\\u003C= 75 years\n* Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group \\[VALG\\] staging system)，the number of metastatic lesions ≤ 5, the number of metastatic organs ≤ 3, and no previous systemic chemotherapy, radiotherapy or immune checkpoint inhibitor treatment.\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n* Expected survival time ≥ 3 months\n* Patients must submit a pre-treatment tumor tissue sample during the study.\n* Adequate hematologic and end organ function\n\nExclusion Criteria:\n\n* Spinal cord compression not definitively treated with surgery and\u002For radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for ≥ 1 week prior to randomization\n* Leptomeningeal disease\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures\n* Uncontrolled or symptomatic hypercalcemia\n* Malignancies other than SCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome\n* History of autoimmune disease, including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease\n* Prior treatment with immune checkpoint blockade therapies\n* Subjects with a condition requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Inhaled or topical steroids, and adrenal replacement steroid are permitted in the absence of active autoimmune disease.\n* Significant cardiovascular disease\n* Prior allogeneic bone marrow transplantation or solid organ transplant\n* Treatment with systemic immunosuppressive medications within 1 weeks prior to randomization\n* History of hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins, carboplatin or etoposide\n* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator",{"count":314,"type":21},62,[24],"This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of adebelizumab combined with carboplatin\u002FCisplatin plus (+) etoposide and concurrent radiotherapy in the first-line treatment of patients with extensive stage oligometastatic small cell lung cancer.",[29,30,236,237,177,238,318,319,176,320],"Carcinoma, Bronchogenic","Bronchial Neoplasms","Small Cell Lung Carcinoma",[322,323,324,211,325],"Extensive stage small cell lung cancer","Oligometastasis","Adebrelimab","Radiotherapy","2023-12-11",{"date":328,"type":42},"2023-12-20",{"date":330,"type":21},"2023-12-10",{"date":332,"type":21},"2026-09-30",{"name":334,"class":49},"Nanfang Hospital, Southern Medical University"]